Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 748

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 748
---
, 2025, and a Form
25-NSE would be filed with the SEC, which would remove Denali’s securities from listing and registration on Nasdaq. Denali did not appeal the Staff’s delisting determination by April 9, 2025,
and the Denali Class A ordinary shares, Public Warrants and Public Units were delisted at the opening of business on April 16, 2025. Trading of the Company’s securities on the OTC Markets commenced shortly after the delisting.

On April 11, 2025, the shareholders of the Company held an extraordinary general meeting of shareholders to consider and vote upon a proposal to amend,
by way of special resolution, the amended and restated memorandum and articles of association of the Company to extend the date by which the Company must either (i) consummate a merger, share exchange, asset acquisition, share purchase,
reorganization or similar business combination involving the Company and one or more businesses or entities or (ii) cease its operations, except for the purpose of winding up, if it fails to complete such initial business combination and redeem
100% of the Company’s Class A ordinary shares, included as part of the units sold in the Company’s IPO April 11, 2025 to December 11, 2025, by electing to extend the date to consummate an initial business combination on a
monthly basis for up to eight (8) times by an additional one month each time, unless the closing of the Company’s initial business combination has occurred, without the need for any further approval of the Company’s shareholders,
provided that the Sponsor (or its affiliates or permitted designees or a third party) will deposit into the Trust Account for each such one-month extension $0.02 per public share that remains outstanding and
is not redeemed prior to any such one-month extension, unless the closing of the Company’s initial business combination has occurred, in exchange for a
non-interest bearing promissory note payable upon consummation of an initial business combination.

In connection
with the extraordinary general meeting on April 11, 2025, shareholders holding 708,098 public shares exercised their right to redeem such shares for a pro rata portion of the funds in the Company’s Trust Account. As a result,
approximately $8.6 million (approximately $12.17 per share) was removed from the Trust Account to pay such holders. Following redemptions, the Company had 43,739 public shares outstanding.

On April 11,